Herein, we have a study design to evaluate the safety and efficacy of the dual-immunology therapy (CTLA-4 inhibitor, SHR-8068 and anti-PD-L1 antibody, adebrelimab) combined with antiangiogenic agent (bevacizumab) in late-line line for advanced CRC patients. This evidence concerns the gene CTLA4 and colorectal carcinoma.